Recent research provided evidence that effective H1-antihistaminic drugs need not exert a central and sedative action. Non-sedative H1-antihistaminics can aptly replace older combined preparations of classical H1-antihistaminics, motivated by an effort to weaken their sedative action by the concurrent administration of pharmaceutical preparations with a central stimulating action (e.g. Bromadryl F). The new group of non-sedative histamine H1-antagonists uses in a rational way changes of the physical and chemical properties of these substances or differences in their affinity to histamine H1-receptors in different areas to reduce the incidence of typical undesirable effects.